Antimicrobial Resistance in Canada: Trends, Risks & What You Can Do

Dive into up-to-date data on antimicrobial resistance Canada, learn the causes, see what institutions are doing, and find concrete actions you or your clinic can take.

Introduction

Antimicrobial resistance in Canada is no longer a distant worry—it’s increasingly part of our daily healthcare reality. Around the world, microbes that once responded reliably to antibiotics are adapting and evolving. In Canada, recent surveillance data show upward trends in several key resistant pathogens.
In this article, we’ll dig into what antimicrobial resistance (AMR) really means, where Canada stands today, why resistance is growing, what institutions are doing about it, and most importantly, what you as a patient, clinician or citizen can do to slow it down. By the end, you’ll have a grounded, Canada-specific view and practical steps you can use or share.

Here, “antimicrobial resistance Canada” refers to resistance occurring in Canadian settings—hospitals, communities, public health systems, and beyond.

What Is Antimicrobial Resistance (AMR)? — The Basics

Before diving into data, let’s get clear on fundamentals.

Antimicrobials, Antibiotics, and Resistance

• Antimicrobials is an umbrella term: it includes antibiotics (against bacteria), antivirals, antifungals, and antiparasitics.
• Antibiotic resistance is a subset: bacteria evolve or acquire the ability to survive in the presence of antibiotics intended to kill them or stop growth.
• AMR refers broadly to any microbe (bacteria, viruses, fungi, parasites) becoming resistant to the treatments used against them.

Resistance arises through mutation (a random genetic change), horizontal gene transfer (bacteria passing resistance genes to others), or selection pressure (when drugs kill susceptible microbes, leaving resistant ones behind).

When bacteria become drug-resistant, infections become more difficult to treat, requiring stronger or more toxic medications. In worst cases, there may be no effective treatment—leading to severe illness or death. Terms like “superbugs” or “drug-resistant bacteria” often refer to pathogens with resistance to multiple antimicrobial classes.

Why Does AMR Matter?

Here’s why AMR is more than a technical issue:

• Higher risk in medical care: Procedures like surgery, chemotherapy, organ transplants, or treatments in intensive care depend on reliable antimicrobials.
• Longer hospital stays & more cost: Resistant infections often lead to prolonged care, extra diagnostics, and more expensive drugs.
• Public health threat: Resistant microbes can spread between people, across communities and hospitals, turning “ordinary” infections into dangerous ones.
• Global and local interplay: Even if Canada does well, resistant strains from elsewhere (through travel, trade, pets, food) can arrive here.

Because of all this, monitoring resistance, controlling spread (infection control), and reducing unnecessary use of antimicrobials are foundational to preserving effectiveness.

AMR in Canada — Latest Data & Trends

Canada’s efforts to monitor and report antimicrobial resistance are coordinated largely through the Canadian Antimicrobial Resistance Surveillance System (CARSS). This platform integrates data from multiple surveillance systems—human health, veterinary, environmental, and antimicrobial use—to give a fuller picture of resistance trends.
According to the 2024 CARSS summary, multiple five-year indicators (2018–2022) show worsening trends in certain pathogens. For example: vancomycin-resistant Enterococcus and carbapenemase-producing Enterobacterales are rising, while Clostridioides difficile infections and MRSA bloodstream infections in healthcare settings are stable.
CARSS also notes that community-associated MRSA, drug-resistant Neisseria gonorrhoeae, and multidrug-resistant Streptococcus pneumoniae infections are trending upward.

Beyond CARSS, hospital surveillance via the Canadian Nosocomial Infection Surveillance Program (CNISP) confirms this mixed picture: some pathogens hold steady, others increase. For instance, rates of VRE bloodstream infections have seen a notable rise, and carbapenemase-producing Enterobacterales (CPE) infections in acute care hospitals are increasing. In 2023, hospitals reported 138 CPE infections across 97 facilities—an incidence of 0.14 per 10,000 patient-days, up from just 0.03 in 2010.

These data illustrate that while not every region or pathogen is worsening, the overall trend is concerning. Some resistance is creeping upward, especially in hard-to-treat bugs.

Regional & Provincial Patterns & Disparities

While national figures tell a broad story, there’s meaningful variation across Canada—among provinces, urban vs rural settings, and populations with unequal access to care.

• Not all provinces publicly release AMR breakdowns, but surveillance partners often indicate higher burdens in denser provinces (Ontario, Quebec, British Columbia).
• Remote, northern, and Indigenous communities may face extra challenges: fewer diagnostic labs, longer transport times for samples, limited hospital resources, and higher baseline rates of some infections.
• In those settings, delays in detection or outbreak response can magnify spread of resistant organisms.
• Equity-oriented plans must ensure these regions aren’t left behind as resistance intensifies nationwide.

Because of these disparities, national strategies emphasize harmonizing surveillance and capacity across provinces so that data (and interventions) aren’t skewed toward better-resourced regions.

Surveillance in Hospitals & Healthcare Settings

Hospitals are frontline battlegrounds in the fight against antimicrobial resistance. Thanks to the Canadian Nosocomial Infection Surveillance Program (CNISP), Canada has multi-year data on healthcare-associated infections (HAIs) and resistant organisms.

Trends & Key Findings from CNISP (2019–2023)

• In acute care hospitals, MRSA bloodstream infections (BSIs) and Clostridioides difficile infections (CDI) have remained relatively stable over these years.
• By contrast, vancomycin-resistant Enterococcus (VRE) BSIs have risen modestly, and carbapenemase-producing Enterobacterales (CPE) infections have doubled in incidence (though starting from a low baseline).
• For example, in 2023 CNISP-participating hospitals reported 138 CPE infections across 97 facilities, which equates to around 0.14 per 10,000 patient-days. This is up from 0.03 per 10,000 patient-days in 2010.
• Importantly, most CPE infections are now domestically acquired—around 80–85% in recent years—rather than linked to travel. (That suggests hospital transmission is a major driver).
• CDI rates in hospitals held between 4.90 and 5.35 per 10,000 patient-days. MRSA BSI rates varied between 1.00 and 1.16 per 10,000 days.
• C. auris (a fungus with significant resistance potential) remains rare in Canada.

These observations are drawn from the latest Healthcare-Associated Infections & Antimicrobial Resistance report for Canadian acute care hospitals. (Link: Canada Communicable Disease Report)

What That Tells Us

• A stable MRSA or CDI rate doesn’t guarantee safety — it may reflect plateaued progress, not decline.
• Growing VRE and CPE rates signal that even “low-level” threats should not be ignored.
• The shift toward domestic acquisition of CPE means that containment within Canada is essential; imported cases are no longer the only risk.
• Hospital infection prevention and control (IPC) practices, surveillance, and rapid response are critical in curbing transmission within facilities.

CNISP covers around 100+ acute care hospitals across provinces, but it does not encompass all settings (long-term care, rural hospitals) yet. (CNISP overview)

What Drives AMR in Canada — Underlying Causes

Understanding the mechanisms behind antimicrobial resistance in Canada helps point us to interventions. The growth of AMR doesn’t stem from a single cause—it’s a mix of medical, agricultural, environmental, and systemic factors.

Misuse & Overuse of Antibiotics in Human Medicine

• Many antibiotic prescriptions are for viral illnesses or conditions that would resolve without antimicrobials.
• Some patients stop a course early once symptoms ease, leaving partially exposed bacteria in their system—this can select for resistant strains.
• In community surveys, a significant proportion of Canadians report having used antibiotics in the past year, sometimes without full oversight (e.g. leftover prescriptions).
• In Quebec, a study linked antimicrobial consumption (via wastewater surveillance) with regional resistance spread, showing how human use patterns can be detectable in environmental samples.

Antibiotic Use in Agriculture, Animals & One Health

• Use of antimicrobials in livestock, aquaculture, and companion animals contributes to selection pressure in bacteria that can cross species.
• Canada tracks antimicrobial use in food-producing animals via reports like CAHS’s “Antimicrobial Use in Food-Producing Animals in Canada.”
• Resistant organisms from animals or agricultural runoff can reach soil, water, or even crops—forming environmental reservoirs.

Environmental & Wastewater Pathways

• Effluents from hospitals, pharmaceutical manufacturing, and farms can release antimicrobials or resistant organisms into water systems.
• Wastewater surveillance (in Canada and globally) is becoming a method to monitor AMR trends in a community.
• Natural bacterial populations in soil and water can act as gene banks for resistance determinants, which may transfer to pathogenic bacteria.

Diagnostic & Test Capacity Gaps

• In some settings, standard diagnostics are slow or unavailable, leading clinicians to “prescribe first, test later” (or not at all).
• Without rapid tests, there’s pressure to use broad-spectrum antibiotics empirically, increasing selection risk.
• Smaller or rural clinics may lack access to up-to-date antibiograms or local resistance data.

Weak Incentives for Antibiotic Development

• Unlike chronic medicines, new antibiotics are used sparingly and have uncertain commercial returns.
• Many pharmaceutical companies have pulled back from antibiotic R&D.
• In Canada, regulatory and market access barriers make it difficult for newer “reserve” antimicrobials to gain adoption, limiting treatment options.

How Canada (and Provinces) Are Responding

Canada has amplified its AMR efforts in recent years, shifting from framework to action. The backbone of this push is the Pan-Canadian Action Plan on Antimicrobial Resistance (2023–2027), developed jointly by federal, provincial, and territorial partners.
The Action Plan outlines 10 priority actions spread across 5 pillars: research & innovation, surveillance, stewardship, infection prevention & control, and leadership.

Pan-Canadian Action Plan: Goals & Structure

• The Plan coordinates across human health, veterinary, agriculture, and environmental sectors (One Health approach).
• It emphasizes equity, especially in working with Indigenous communities and underserved regions.
• In its first year (2023–24), Canada has begun rolling out foundational assets like a Compendium of activities, performance metrics, and pilot initiatives in stewardship and surveillance.

The Plan recognizes that prior efforts (for example, the 2017 Federal Framework for Action on AMR) laid groundwork, but more coordinated implementation is needed now.

Policy, Regulation & Oversight

• Health Canada oversees the approval and regulation of antimicrobials in humans and animals; its Veterinary Drugs Directorate plays a major role in setting rules for veterinary drug use.
• The government has committed to improved antimicrobial prescribing guidelines, updated monitoring of antimicrobial use, and supporting stewardship in both human and animal health sectors.
• The Office of the Auditor General recently flagged weaknesses: the Action Plan lacks clearly assigned accountability, deliverable timelines, and access to many “reserve” antibiotics in Canada.

Infection Prevention & Control (IPC) & Stewardship in Healthcare

In hospitals and clinics, Canada is increasing its focus on:

• Antimicrobial stewardship programs (ASPs). These programs coordinate prescribing policies, monitoring, and education across institutions. Many Canadian hospitals require ASPs for accreditation.
• IPC measures: stronger hand hygiene protocols, standardized isolation practices, screening for colonization on hospital admission, and environmental cleaning.
• Data reporting and performance metrics: linking local antibiogram data to stewardship practices, making reporting mechanisms more robust.

Some provinces are advancing their own stewardship efforts. For instance, British Columbia’s medical board offers clinical tools for antimicrobial stewardship across outpatient settings.

Across the animal health side, the Action Plan calls for tighter regulation of antimicrobial use in livestock, improved biosecurity, and monitoring of antimicrobial use in farming. Animal Health Canada and Agriculture Canada are building governance networks to support these goals.

What You (Individuals, Patients, Clinicians) Can Do

It’s not just up to governments and hospitals. Individuals, patients, and clinicians play a major role in slowing resistance. Below are practical steps by role.

For the General Public / Patients

• Don’t demand antibiotics for viral illnesses (like colds or flu)
• Always complete the full course of antibiotics prescribed—don’t stop early
• Avoid using leftover antibiotics or those prescribed to someone else
• If your doctor orders lab or culture tests, ask how antibiotic decisions will depend on results
• Maintain good hygiene: regular hand washing, safe food handling, vaccination
• Learn about local AMR trends or clinic guidance where you live

For Clinicians & Clinics

Below is a sample checklist for clinics and practitioners to strengthen stewardship:

In smaller or rural settings lacking lab access, clinicians can still apply stewardship by adhering strictly to guideline protocols, and consulting telemedicine/lab partners when needed.

Also, clinicians should engage patients in shared decision-making: explaining risks of resistance, when antibiotics help (and when not), and emphasizing the value of “watchful waiting” in certain cases.

Future Outlook & Major Challenges Ahead

AMR is not a static threat—it evolves. What lies ahead for Canada depends heavily on how effectively we scale our responses.

Projected Costs, Health Burden & Economic Drag

• If nothing changes, the healthcare costs linked to antimicrobial-resistant infections in Canada are projected to rise to about CAD 6 billion annually by 2050, based on current infection rates.
• From 2018 to 2050, cumulative loss in Canada’s GDP could reach CAD 268 billion, assuming trends aren’t reversed.
• In 2018, AMR-related hospital costs in Canada were estimated at CAD 1.4 billion and losses to GDP at CAD 2 billion.
• Globally, resistance is projected to push annual health care costs from US$ 66 billion today to US$ 159 billion by 2050.
• In Canada, one analysis estimates that an antimicrobial-resistant MRSA infection alone can cost over CAD 8,000 more than a comparable susceptible infection.

These figures show that AMR isn’t just a health threat—it’s a major economic drag if left unchecked.

Emerging Risks & Pressures

1. Higher resistance base
   Some experts estimate that 26% of bacterial infections in Canada were resistant to first-line treatments by 2018—and that could climb toward 40% by 2050.
   That means more infections require second- or third-line therapies, often with more side effects and cost.
2. Weak antibiotic pipeline
   The number of new classes of antibiotics reaching clinical use is dwindling. Most candidates target existing drug classes, making them vulnerable to the same resistance mechanisms.
3. Gaps in coordination & funding
   Analyses reveal that Canada’s investments in AMR have been stagnant, and policy efforts sometimes lack centralized oversight and accountability.
   The fragmented nature of human health, veterinary, agriculture, and environment sectors makes cohesive, powerful actions difficult.
4. One Health complexity
   Integrating surveillance across humans, animals, and environment (water, soil, wildlife) is essential—but challenging. Variations in data standards, jurisdictional control, and technical capacity create hurdles.
5. Equity & access vulnerabilities
   Remote and Indigenous communities, with limited access to diagnostics and care, may suffer disproportionally. If resistance spreads, outbreaks could disproportionately affect these regions.
6. Climate change and environmental stress
   Warming temperatures, flooding, and environmental disruption can influence bacterial growth, gene transfer, and spread of resistance.

If Canada fails to act boldly, the “ordinary infections” we take for granted today may become much harder or impossible to treat.

Conclusion & What You Can Do

Antimicrobial resistance in Canada is not just a far-off threat—it’s a present challenge. While some resistance trends remain stable, others—especially in VRE and carbapenemase producers—are rising. The costs in lives, dollars, and healthcare burden are mounting.

But this is not a hopeless fight. Canada’s Pan-Canadian Action Plan, strengthened funding, One Health integration, and institutional efforts show momentum is building. Everyone—governments, clinicians, communities, patients—has a part to play.

Your steps matter. If you’re a healthcare provider, prioritize stewardship, diagnostics, and patient education. If you’re a patient or community member, use antibiotics responsibly, practice good hygiene, and stay informed. Encourage your local clinics and hospitals to share antibiogram data or adopt stewardship measures.

FAQ